By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. I’m not a resolutions person but I’ve always loved the start of the year – there is something about turning the page on

By Jason Campagna, biotech executive, as part of the From The Trenches feature of LifeSciVC I recently joined Inventiva Pharma, a late-stage company developing a therapeutic for metabolic disease and MASH, a field that is both scientifically complex and once

By, Arthur Tzianabos, CEO of Lifordi, as part of the From The Trenches feature of LifeSciVC I often hear biotech leaders refer to their company’s technology and approach in terms of the “secret sauce” or “how the sausage gets made.”

This year has truly been a rollercoaster!  The markets started off with optimism, but then collapsed into the spring, only to rebound with enthusiasm in recent months. The cadence of M&A has picked up, creating a tailwind for the sector. 

By Abbas Kazimi, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC Hospitals were never meant to be familiar to me, yet for over twenty years MD Anderson became a place I could navigate by heart: the

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC I’m far from the first person to point out the prolonged market challenges that have depressed the biotech fundraising environment over the past

By Mike Gilman, serial entrepreneur and veteran biotech executive, as part of the From The Trenches feature of LifeSciVC My thesis advisor, Mike Chamberlin, passed away last week. I owe much of who I am as a scientist to him.

At the end of the day, biotech venture capital is a business and driving returns is the ultimate metric. For twenty years, to deliver on that, I’ve embraced what I call the “first principle” of early stage biotech investing: if

Talented people make the magic happen in biotech.  This is the second post in my “Twenty Years In Early Stage Venture” trifecta. Yesterday’s was on Science. Today we’re talking about the People part of biotech. After a couple decades and

In the blink of an eye, twenty years have passed: in mid-October 2005, I joined Atlas Venture as a principal on the global life science team.  We closed Fund VII a few months after I joined; and, just a few

By Ram Aiyar, CEO of Korro Bio, as part of the From The Trenches feature of LifeSciVC Let me tell you a secret that most biotech executives won’t admit at cocktail parties: we’re all making it up as we go

By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC Building the right team is a popular topic because it is difficult and a company’s success hinges on it. In a cash-crunched biotech